Skip to main navigation
Close
Main navigation
Advocacy
Issue Overview
Prescription for Savings
Sustainable Supply Chain
Biosimilars
IP & Patent Reform
Medicaid Generics Penalty
State Legislation
Trade
Events
Our Impact
About Us
Generic Quality
About the Association
Our Team
Our Members
Meet Our Board
Social Commitment
Generic Medicines
Biosimilars
Careers
Contact Us
Resources
Search Resources
2020 Access and Savings Report
Supply Chain Blueprint
Industry Response to COVID-19
Press Releases
Blog
State Lawmaker Toolkit
Amicus Briefs
Join
Take Action
Menu
In the News
- View AAM CEO Dan Leonard's blog on the essential role generic drugs play during COVID-19
Learn More
Close
Breadcrumb
Home
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Report
Feb 22, 2021
| Erica Klinger
Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets
Report
Feb 9, 2021
| Erica Klinger
White Paper: Potential Savings from Accelerating U.S. Approval of Complex Generics
Report
Oct 6, 2020
| Erica Klinger
White Paper: Nitrosamines — An Industry Position Paper Based on Risk
Report
Sep 29, 2020
| Erica Klinger
2020 Generic Drug & Biosimilars Access and Savings in the U.S. Report
Report
Apr 30, 2020
| Erica Klinger
A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain
Report
Feb 20, 2020
| Craig Burton
White Paper: Medicare and Commercial Plans Fail to Get New Generics to Patients
Report
Jan 23, 2020
| Craig Burton
White Paper: Sidelined: How Seniors Miss Out On Savings Available Through Generic Substitution
Report
Jan 1, 2020
| Erica Klinger
The Unintended Economics of the BLOCKING Act
Report
Sep 20, 2019
| Craig Burton
White Paper: Access Denied: Why New Generics Are Not Reaching America's Seniors
Report
Sep 18, 2019
| Erica Klinger
Report: 2019 Generic Drug & Biosimilars Access & Savings in the U.S.
Report
Sep 9, 2019
| Craig Burton
White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption
Report
Jun 25, 2019
| Christine Simmon
White Paper (Part 1) Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America's Patients
Load More
Advocacy
Issue Overview
Prescription for Savings
Sustainable Supply Chain
Biosimilars
IP & Patent Reform
Medicaid Generics Penalty
State Legislation
Trade
Events
Access! 2021
GRx+Biosims 2021
Our Impact
About Us
Generic Quality
About the Association
Our Team
Our Members
Meet Our Board
Social Commitment
Generic Medicines
Biosimilars
Careers
Contact Us
Resources
Search Resources
2020 Access and Savings Report
Supply Chain Blueprint
Industry Response to COVID-19
Press Releases
Blog
State Lawmaker Toolkit
Amicus Briefs
Join
Take Action